Drug utilization and medication adherence for the treatment of psoriatic arthritis: an Italian study
DOI:
https://doi.org/10.33393/grhta.2024.3204Keywords:
Adherence, bDMARDs, Biosimilar, Persistence, Psoriatic arthritisAbstract
Introduction: This study aims to evaluate the persistence, treatment adherence and drug cost associated with biologic and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) in the management of psoriatic arthritis (PsA) in Italy, with a focus on biosimilar drugs.
Methods: This was a retrospective observational study involving eight hospital pharmacies, between January 2017 and December 2020, on naïve patients with at least one b/tsDMARD dispensation indicated for PsA. Patients were followed up for 12 months and persistence and adherence were evaluated by proportion of days covered (PDC). The originator and biosimilar for adalimumab and etanercept were compared. Furthermore, the real annual cost per patient based on adherence to therapy was calculated.
Results: Patients initiating b/tsDMARDs for PsA had a mean persistence of 263 days and 48.6% remained persistent for 1 year. Adherent patients (PDC ≥ 0.8) were 47.6% for the overall population. Similar persistence and adherence were observed between patients treated with the adalimumab originator and its biosimilar, while patients treated with the etanercept originator showed lower persistence and adherence compared to those treated with its biosimilar (mean persistence: 222 vs. 267 days, patient persistent at 1 year: 29.4% vs. 51.5%, mean PDC: 0.53 vs. 0.70, adherent patients: 23.5% vs. 51.5%). The average annual drug cost ranged from €8,724 (etanercept) to €14,783 (ustekinumab), with an annual saving of more than €2,500 by using biosimilars.
Conclusion: Poor adherence to medications contributes to suboptimal clinical outcomes. The comparison between biosimilar and originator offers further evidence in support of the biosimilar to optimizing resources in healthcare.
Downloads
References
Coates LC, Helliwell PS. Psoriatic arthritis: state of the art review. Clin Med (Lond). 2017;17(1):65-70. https://doi.org/10.7861/clinmedicine.17-1-65 PMID:28148584
Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. Rheum Dis Clin North Am. 2015;41(4):545-568. https://doi.org/10.1016/j.rdc.2015.07.001 PMID:26476218
Gladman DD. Current concepts in psoriatic arthritis. Curr Opin Rheumatol. 2002;14(4):361-366. https://doi.org/10.1097/00002281-200207000-00005 PMID:12118168
Brockbank J, Gladman D. Diagnosis and management of psoriatic arthritis. Drugs. 2002;62(17):2447-2457. https://doi.org/10.2165/00003495-200262170-00004 PMID:12421102
Ibrahim G, Waxman R, Helliwell PS. The prevalence of psoriatic arthritis in people with psoriasis. Arthritis Rheum. 2009;61(10):1373-1378. https://doi.org/10.1002/art.24608 PMID:19790120
Khraishi M, Chouela E, Bejar M, et al. High prevalence of psoriatic arthritis in a cohort of patients with psoriasis seen in a dermatology practice. J Cutan Med Surg. 2012;16(2):122-127. https://doi.org/10.2310/7750.2011.10101 PMID:22513065
Mease PJ, Gladman DD, Papp KA, et al. Prevalence of rheumatologist-diagnosed psoriatic arthritis in patients with psoriasis in European/North American dermatology clinics. J Am Acad Dermatol. 2013;69(5):729-735. https://doi.org/10.1016/j.jaad.2013.07.023 PMID:23981683
D’Angelo S, Atzeni F, Benucci M, et al. Management of psoriatic arthritis: a consensus opinion by expert rheumatologists. Front Med (Lausanne). https://doi.org/10.3389/fmed.2023.1327931 PMID:38098852
Harrison SR, Aung Din BNR, Marzo-Ortega H, Helliwell PS. Recent advances in the management of psoriatic arthritis: practical considerations. Pol Arch Intern Med. 2024;134(1):16639; Epub ahead of print. PMID:38164520 https://doi.org/10.20452/pamw.16639 PMID:38164520
Gossec L, Baraliakos X, Kerschbaumer A, et al. EULAR recommendations for the management of psoriatic arthritis with pharmacological therapies: 2019 update. Ann Rheum Dis. 2020;79(6):700-712. https://doi.org/10.1136/annrheumdis-2020-217159 PMID:32434812
Coates LC, Corp N, van der Windt DA, O’Sullivan D, Soriano ER, Kavanaugh A. GRAPPA treatment recommendations: 2021 update. J Rheumatol. 2022;49(6)(suppl 1):52-54. https://doi.org/10.3899/jrheum.211331 PMID:35293339
Chaudri NA. Adherence to long-term therapies evidence for action. Ann Saudi Med. 2004;24(3):221-222. https://doi.org/10.5144/0256-4947.2004.221
Haddad A, Gazitt T, Feldhamer I, et al. Treatment persistence of biologics among patients with psoriatic arthritis. Arthritis Res Ther. 2021;23(1):44. https://doi.org/10.1186/s13075-021-02417-x PMID:33514410
Murage MJ, Tongbram V, Feldman SR, et al. Medication adherence and persistence in patients with rheumatoid arthritis, psoriasis, and psoriatic arthritis: a systematic literature review. Patient Prefer Adherence. 2018;12:1483-1503. https://doi.org/10.2147/PPA.S167508 PMID:30174415
Smolen JS, Goncalves J, Quinn M, Benedetti F, Lee JY. Era of biosimilars in rheumatology: reshaping the healthcare environment. RMD Open. 2019;5(1):e000900. https://doi.org/10.1136/rmdopen-2019-000900 PMID:31245050
Yeaw J, Benner JS, Walt JG, Sian S, Smith DB. Comparing adherence and persistence across 6 chronic medication classes. J Manag Care Pharm. 2009;15(9):728-740. https://doi.org/10.18553/jmcp.2009.15.9.728 PMID:19954264
Prieto-Merino D, Mulick A, Armstrong C, et al. Estimating proportion of days covered (PDC) using real-world online medicine suppliers’ datasets. J Pharm Policy Pract. 2021;14(1):113. https://doi.org/10.1186/s40545-021-00385-w PMID:34965882
Anghel LA, Farcaş AM, Oprean RN. Medication adherence and persistence in patients with autoimmune rheumatic diseases: a narrative review. Patient Prefer Adherence. 2018;12:1151-1166. https://doi.org/10.2147/PPA.S165101 PMID:30013327
Oelke KR, Chambenoit O, Majjhoo AQ, Gray S, Higgins K, Hur P. Persistence and adherence of biologics in US patients with psoriatic arthritis: analyses from a claims database. J Comp Eff Res. 2019;8(8):607-621. https://doi.org/10.2217/cer-2019-0023 PMID:30912454
Walsh JA, Adejoro O, Chastek B, Palmer JB, Hur P. Treatment patterns among patients with psoriatic arthritis treated with a biologic in the United States: descriptive analyses from an administrative claims database. J Manag Care Spec Pharm. 2018;24(7):623-631; Epub ahead of print. https://doi.org/10.18553/jmcp.2018.24.7.623 PMID:29952704
Bonafede M, Fox KM, Watson C, Princic N, Gandra SR. Treatment patterns in the first year after initiating tumor necrosis factor blockers in real-world settings. Adv Ther. 2012;29(8):664-674. https://doi.org/10.1007/s12325-012-0037-5 PMID:22886712
Zhang HF, Gauthier G, Hiscock R, Curtis JR. Treatment patterns in psoriatic arthritis patients newly initiated on oral nonbiologic or biologic disease-modifying antirheumatic drugs. Arthritis Res Ther. 2014;16(4):420. https://doi.org/10.1186/s13075-014-0420-5 PMID:25146329
Zhu B, Edson-Heredia E, Gatz JL, Guo J, Shuler CL. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study. Clin Ther. 2013;35(9):1376-1385. https://doi.org/10.1016/j.clinthera.2013.07.328 PMID:23954091
Chastek B, White J, Van Voorhis D, Tang D, Stolshek BS. A retrospective cohort study comparing utilization and costs of biologic therapies and JAK inhibitor therapy across four common inflammatory indications in adult US managed care patients. Adv Ther. 2016;33(4):626-642. https://doi.org/10.1007/s12325-016-0312-y PMID:26970958
Sewerin P, Borchert K, Meise D, Schneider M, Mahlich J. Real-world treatment persistence with biologic disease-modifying antirheumatic drugs among German patients with psoriatic arthritis – a retrospective database study. Rheumatol Ther. 2021;8(1):483-497. https://doi.org/10.1007/s40744-021-00286-z PMID:33611778
Perrone V, Losi S, Filippi E, Sangiorgi D, Degli Esposti L. Pattern of drug use in patients with psoriatic arthritis in Italy: study in a real-world setting. Expert Rev Pharmacoecon Outcomes Res. 2021;21(4):721-727. https://doi.org/10.1080/14737167.2021.1880322 PMID:33472454
Rosenberg V, Chodick G, Xue Z, Faccin F, Amital H. Real-world data of adherence and drug survival of biologics in treatment-naïve and treatment-experienced adult patients with rheumatoid arthritis. Adv Ther. 2023;40(10):4504-4522. https://doi.org/10.1007/s12325-023-02607-w PMID:37566157
Murage MJ, Princic N, Park J, et al. Treatment patterns and health care costs among patients with psoriatic arthritis treated with biologic or targeted synthetic disease-modifying antirheumatic drugs. J Manag Care Spec Pharm. 2022;28(2):206-217.https://doi.org/10.18553/jmcp.2022.28.2.206 PMID:35098751
Menditto E, Cahir C, Malo S, et al. Persistence as a robust indicator of medication adherence-related quality and performance. Int J Environ Res Public Health. 2021;18(9):4872. Published 2021 May 3. https://doi.org/10.3390/ijerph18094872
Perrone V, Losi S, Filippi E, et al. Analysis of the pharmacoutilization of biological drugs in psoriatic arthritis patients: a real-world retrospective study among an Italian population. Rheumatol Ther. 2022;9(3):875-890. https://doi.org/10.1007/s40744-022-00440-1 PMID:35316515
Esposti LD, Perrone V, Sangiorgi D, et al. Analysis of drug utilization and health care resource consumption in patients with psoriasis and psoriatic arthritis before and after treatment with biological therapies. Biologics. 2018;12:151-158. https://doi.org/10.2147/BTT.S168691 PMID:30518996
Pina Vegas L, Penso L, Sbidian E, Claudepierre P. Influence of sex on the persistence of different classes of targeted therapies for psoriatic arthritis: a cohort study of 14 778 patients from the French health insurance database (SNDS). RMD Open. 2023;9(4):e003570. https://doi.org/10.1136/rmdopen-2023-003570 PMID:38114199
Lubrano E, Scriffignano S, Fatica M, et al. Psoriatic arthritis in males and females: differences and similarities. Rheumatol Ther. 2023;10(3):589-599. https://doi.org/10.1007/s40744-023-00535-3 PMID:36795290
Eder L, Thavaneswaran A, Chandran V, Gladman DD. Gender difference in disease expression, radiographic damage and disability among patients with psoriatic arthritis. Ann Rheum Dis. 2013;72(4):578-582. https://doi.org/10.1136/annrheumdis-2012-201357 PMID:22589379
Kay J, Schoels MM, Dörner T, et al; Task Force on the Use of Biosimilars to Treat Rheumatological Diseases. Consensus-based recommendations for the use of biosimilars to treat rheumatological diseases. Ann Rheum Dis. 2018;77(2):165-174. https://doi.org/10.1136/annrheumdis-2017-211937 PMID:28866648
Fleischmann R. Editorial: the American College of Rheumatology white paper on biosimilars: it isn’t all white – there is some gray and black. Arthritis Rheumatol. 2018;70(3):323-325. https://doi.org/10.1002/art.40402 PMID:29411540
Larid G, Baudens G, Dandurand A, et al. Differential retention of adalimumab and etanercept biosimilars compared to originator treatments: results of a retrospective French multicenter study. Front Med (Lausanne). 2022;9:989514. https://doi.org/10.3389/fmed.2022.989514 PMID:36275803
Di Giuseppe D, Lindstrom U, Bower H, et al. Comparison of treatment retention of originator vs biosimilar products in clinical rheumatology practice in Sweden. Rheumatology (Oxford). 2022;61(9):3596-3605. https://doi.org/10.1093/rheumatology/keab933 PMID:34919663
van Adrichem RCS, Voorneveld HJE, Waverijn GJ, Kok MR, Bisoendial RJ. The non-medical switch from reference adalimumab to biosimilar adalimumab is highly successful in a large cohort of patients with stable inflammatory rheumatic joint diseases: a real-life observational study. Rheumatol Ther. 2022;9(4):1109-1118 https://doi.org/10.1007/s40744-022-00465-6 PMID:35655028
Blauvelt A, Leonardi CL, Gaylis N, et al. Treatment with SDZ-ADL, an adalimumab biosimilar, in patients with rheumatoid arthritis, psoriasis, or psoriatic arthritis: results of patient-reported outcome measures from two phase III studies (ADMYRA and ADACCESS). BioDrugs. 2021;35(2):229-238. https://doi.org/10.1007/s40259-021-00470-1 PMID:33651341
Schmalzing M, Kellner H, Askari A, et al. Real-world effectiveness and safety of SDZ ETN, an etanercept biosimilar, in patients with rheumatic diseases: final results from multi-country COMPACT study. Adv Ther. 2024 Jan;41(1):315-330. https://doi.org/10.1007/s12325-023-02706-8 PMID:37950790
Pinto AS, Cunha MM, Pinheiro F, et al. Effectiveness and safety of original and biosimilar etanercept (Enbrel® vs Benepali®) in bDMARD-naïve patients in a real-world cohort of Portugal. ARP Rheumatol. 2022 Apr-Jun;1(2):109-116. English. PMID: 35810368.
Agenzia Italiana del Farmaco. Secondo Position Paper AIFA sui Farmaci Biosimilari 27 Marzo 2018. https://www.aifa.gov.it/en/farmaci-biosimilari. Accessed July 2024.
Addis A. Biosimilari: l’Agenzia Italiana del Farmaco prende posizione [Biosimilars: Italian Medicines Agency takes position.]. Recenti Prog Med. 2018 Apr;109(4):214-215. Italian. https://doi.org/10.1701/2896.29191. PMID: 29689035.
Belhassen M, Tubach F, Hudry C, et al. Impact of persistence with tumour necrosis factor inhibitors on healthcare resource utilization and costs in chronic inflammatory joint diseases. Br J Clin Pharmacol. 2021;87(1):163-177. https://doi.org/10.1111/bcp.14387 PMID:32441383
Zagni E, Frassi M, Mariano GP, et al. A real-world economic analysis of biologic therapies for psoriatic arthritis in Italy: results of the CHRONOS observational longitudinal study. BMC Health Serv Res. 2022;22(1):1537. https://doi.org/10.1186/s12913-022-08954-8 PMID:36527051
Degli Esposti L, Perrone V, Sangiorgi D, et al. Therapeutic strategies utilization and resource consumption in patients treated for psoriatic arthritis: findings from a real-world analysis in an Italian setting. Patient Prefer Adherence. 2019;13:187-194. Published 2019 Jan 22. https://doi.org/10.2147/PPA.S178603
Perrone V, Giacomini E, Sangiorgi D, et al. Treatment pattern analysis and health-care resource consumption on patients with psoriatic arthritis or ankylosing spondylitis treated with biological drugs in a northern Italian region. Ther Clin Risk Manag. 2020;16:509-521. https://doi.org/10.2147/TCRM.S248390 PMID:32606710
Car E, Vulto AG, Houdenhoven MV, Huys I, Simoens S. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends. Front Pharmacol. 2023;14:1151764. Published 2023 Apr 21. https://doi.org/10.3389/fphar.2023.1151764
Rojas-Giménez M, Mena-Vázquez N, Romero-Barco CM, et al. Effectiveness, safety and economic analysis of Benepali in clinical practice. Reumatol Clin (Engl Ed). 2021;17(10):588-594. https://doi.org/10.1016/j.reumae.2020.06.010 PMID:34823826
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 The authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Accepted 2024-09-09
Published 2024-10-09
